Vision Complex: Peptide Support for Eyes, Brain, and Vascular Health

# Vision Complex: Peptide Support for Eyes, Brain, and Vascular Health

Vision loss is one of the most feared consequences of aging. In national surveys, Americans consistently rank losing their eyesight as their greatest health concern — above cancer, heart disease, and cognitive decline. Yet most people do very little to proactively protect their vision beyond annual eye exams and hoping for the best.

After 20 years as a nurse, I've seen how vision loss devastates quality of life. Falls, social isolation, depression, loss of independence — the downstream effects are enormous. That's why I'm particularly interested in Vision Complex, a Khavinson peptide bioregulator formulation that takes a systems-level approach to visual health: Visoluten (A-11) for the eyes, Cerluten (A-5) for the brain, and Ventfort (A-3) for the vascular system.

The logic is compelling. Vision isn't just about your eyes — it's about the entire visual pathway from retina to visual cortex, supplied by some of the most delicate vasculature in the body.

Why Vision Declines: More Than Just the Eyes

Age-related vision loss has multiple overlapping causes, and most of them extend beyond the eyeball itself:

Effective vision preservation must address all of these factors. A supplement that only targets the retina ignores the vascular and neural components that are equally critical.

Visoluten (A-11): The Retinal Peptide

Visoluten is a peptide bioregulator derived from eye tissue, specifically targeting retinal cells. Developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology, Visoluten contains short-chain peptides that interact with gene regulatory regions in retinal cells to normalize protein synthesis.

The retina is a remarkably complex structure — essentially an extension of the brain that happens to be located in the eye. It contains over 100 million photoreceptor cells (rods and cones), along with bipolar cells, ganglion cells, amacrine cells, and retinal pigment epithelium (RPE) cells. The RPE is particularly important: it provides metabolic support to the photoreceptors, recycles visual pigments, and forms part of the blood-retinal barrier.

Khavinson's research on retinal peptides has been among his most clinically validated work. In controlled clinical studies, Visoluten (originally studied under the name Retinalamin, the injectable form of the same peptide complex) demonstrated measurable improvements in visual function:

Visoluten represents the oral form of this research — making retinal peptide bioregulation accessible without the need for injections.

Cerluten (A-5): The Brain Peptide for Visual Processing

Here's a fact that most people don't consider: roughly 30% of your cerebral cortex is devoted to visual processing. The primary visual cortex (V1), along with numerous higher visual processing areas, interprets the raw signals from your retina and constructs the visual experience you perceive.

Age-related changes in these brain regions affect vision independently of what's happening in the eye itself. Research has demonstrated that:

Cerluten contains brain-derived peptides that support neuronal function and neural tissue maintenance. By including Cerluten in Vision Complex, the formulation addresses the cortical processing component of vision — something that eye-focused supplements completely miss.

Khavinson's research demonstrated that brain-derived peptides can restore electrical activity in neurons exposed to stress conditions and support gene expression patterns associated with neuroprotection (Khavinson et al., 2014, *Advances in Gerontology*, PMID: 25826985). For visual function, this translates to better cortical processing of the signals your retina sends.

Ventfort (A-3): The Vascular Peptide for Ocular Blood Flow

The retina receives its blood supply from two sources: the central retinal artery (which supplies the inner retinal layers) and the choroidal circulation (which supplies the outer retina and RPE). Both are end-arteries — they have no backup supply. When these vessels fail, the tissue they serve dies.

This makes retinal vasculature among the most critical — and most vulnerable — blood vessels in the body. Several of the most common causes of vision loss are primarily vascular:

Ventfort contains peptides derived from vascular tissue that support blood vessel wall integrity. Research has demonstrated that vascular peptide bioregulators help normalize elastin and collagen synthesis in arterial walls, supporting the structural integrity of the vasculature (Khavinson et al., 2008, *Bulletin of Experimental Biology and Medicine*, PMID: 19110595).

For ocular health specifically, maintaining healthy retinal and choroidal vasculature is essential for delivering the enormous quantities of oxygen and nutrients the retina requires and for removing metabolic waste that would otherwise accumulate and cause damage.

The Eye-Brain-Vascular Triad: A Systems Approach

Vision Complex is designed around a fundamental insight from modern ophthalmology: the visual system is a triad of retinal tissue, neural processing, and vascular supply. Failure in any one component compromises the entire system.

This systems perspective is supported by current research:

By addressing all three components — retinal tissue, brain tissue, and vascular tissue — Vision Complex takes an approach that is aligned with how the visual system actually functions.

Macular Degeneration Prevention: What the Science Says

AMD deserves special attention because it is the leading cause of central vision loss in adults over 50. The disease progresses from early stages (drusen deposits under the retina) to advanced stages (geographic atrophy in dry AMD, or neovascularization in wet AMD).

Current preventive strategies are limited:

Peptide bioregulation offers a complementary approach by supporting the cellular health of the RPE and photoreceptors directly, while simultaneously maintaining the vascular infrastructure they depend on. The Khavinson laboratory's clinical work with retinal peptides showed improvements in patients with existing AMD, suggesting potential for both prevention and management (Khavinson, 2002, *Neuroendocrinology Letters*, PMID: 12163955).

Who May Benefit from Vision Complex?

Based on the research and mechanism of action, Vision Complex may be relevant for adults who:

My Perspective as a Nurse

Vision is one of those things people take for granted until it starts to go. By then, the damage is often already significant. In my clinical career, the patients who fared best were those who took proactive measures early — not just eye exams, but active support for the biological systems that vision depends on.

Vision Complex represents exactly the kind of proactive, systems-level approach that I wish more of my patients had access to. It doesn't replace regular eye care — it complements it by supporting the retinal, neural, and vascular tissue that your vision depends on at the cellular level.

If you're interested in a research-backed approach to protecting your vision, [visit our shop](/shop) to learn more about Vision Complex and our complete peptide bioregulator collection.

---

*The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. If you have an eye condition, continue working with your ophthalmologist or optometrist. Peptide bioregulators are dietary supplements and have not been evaluated by the FDA.*

References

1. Wong WL et al. (2014). Global prevalence of AMD. *The Lancet Global Health*, 2(2), e106-e116.
2. Khavinson VK et al. (2008). Retinalamin in diabetic retinopathy. *Bulletin of Experimental Biology and Medicine*, 146(4), 457-461.
3. Khavinson VK (2002). Peptides and ageing. *Neuroendocrinology Letters*, 23(Suppl 3), 11-144.
4. Owsley C (2011). Aging and vision. *Annual Review of Vision Science*, 51(1), 1-13.
5. Khavinson VK et al. (2014). Short peptides stimulate cell regeneration. *Advances in Gerontology*, 4(2), 88-93.
6. Cheung N et al. (2010). Diabetic retinopathy. *The Lancet*, 376(9735), 124-136.
7. Flammer J et al. (2002). Vascular dysregulation in glaucoma. *Progress in Retinal and Eye Research*, 21(4), 359-393.
8. Age-Related Eye Disease Study 2 Research Group (2013). AREDS2. *JAMA*, 309(19), 2005-2015.
9. Baker ML et al. (2008). Retinal signs and stroke. *Neurology*, 70(18), 1581-1587.